Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Review Pathway
Sen. Burr asks FDA whether fee revenue should be rebated for not meeting some PDUFA V goals.
India has outlined measures to fast track the regulatory process for certain combination products for HIV and hepatitis, and thereby facilitate early access to these treatments.
Jeffrey Shuren and Janet Woodcock tell Senate committee that agency is more concerned with implementing combination product provisions of the 21st Century Cures Act.
Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to quicken the pace of launches to potentially overcome China’s “drug lag” and that may also bolster multinationals’ interest and activity in the country.
The latest drug development news and highlights from our FDA Performance Tracker.
No sponsor is named in the citizen petition, but it was filed on behalf of an applicant that has had an appeal of a designation decision 'under consideration' for 18 months and counting.
Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.
All marketing approval applications submitted via Europe’s decentralized procedure are being processed under a new pilot that should help regulators validate applications faster. The pilot might also give companies a better understanding of the validation process and how omissions or mistakes in their documentation might invalidate or delay their applications.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.